Liraglutide is a once-daily injection, and its dose depends on why it is prescribed. The weight-management label and the diabetes label use the same molecule at different ceilings.
This page sets out what each label states, why the steps are a week apart, and what the dose-finding trial showed about more versus less. The side effects that drive the slow start are covered in liraglutide side effects.
The weight-management schedule
The Saxenda label starts every patient aged 12 and older at 0.6 mg daily for one week [1]. It then rises 0.6 mg each week until 3 mg.
| Week | Daily dose |
|---|---|
| 1 | 0.6 mg |
| 2 | 1.2 mg |
| 3 | 1.8 mg |
| 4 | 2.4 mg |
| 5 and onward | 3 mg |
For adults, the label calls 3 mg the recommended dose and describes the lower doses as “for titration only” [1]. It says to stop the drug if an adult cannot tolerate 3 mg.
If a step is not tolerated, the label allows delaying the next increase by about one more week. The pen is a 6 mg/mL, 3 mL device that delivers the five fixed doses.
Adolescents
For patients aged 12 to 17, the label also aims for 3 mg daily, but allows 2.4 mg if 3 mg is not tolerated [1]. Escalation may take up to 8 weeks in this group.
The label’s check here is BMI, not weight: stop if BMI has not fallen at least 1% after 12 weeks on the maintenance dose.
The diabetes schedule
The Victoza label is for glycemic control in type 2 diabetes and for cutting cardiovascular risk in adults with diabetes and heart disease [2]. It starts at 0.6 mg daily for one week.
That starting dose, the label says, is meant to reduce stomach side effects and does not control blood sugar. The dose then rises to 1.2 mg, and to a maximum of 1.8 mg if more control is needed.
So the diabetes ceiling is 1.8 mg, and the weight dose is 3 mg. Both labels say not to combine liraglutide with another liraglutide product.
Why the dose is stepped
Both labels tie the slow start to gastrointestinal side effects [1] [2]. Nausea was the most common reason people stopped in the weight trials.
In the Saxenda label’s pooled trials, 9.8% on the drug and 4.3% on placebo stopped because of side effects. Nausea alone accounted for 2.9% against 0.2%.
Liraglutide’s half-life is about 13 hours, which is why it is dosed daily [1]. The weekly GLP-1 drugs step up monthly instead, as set out in semaglutide dosage.
Does a higher dose do more?
The dose-ranging trial randomized 564 adults with obesity, without diabetes, to four liraglutide doses, placebo or an oral comparator for 20 weeks [3]. Everyone followed a 500 kcal-a-day deficit diet.
| Group | Mean weight lost |
|---|---|
| Placebo | 2.8 kg |
| 1.2 mg | 4.8 kg |
| 1.8 mg | 5.5 kg |
| 2.4 mg | 6.3 kg |
| 3.0 mg | 7.2 kg |
More lost at least 5% of their weight on 3.0 mg (76%) than on placebo (30%). Nausea and vomiting were more common on liraglutide, and mostly passed.
The larger SCALE trial then tested 3.0 mg against placebo in 3,731 adults for 56 weeks [4]. Mean loss was 8.4 kg on liraglutide and 2.8 kg on placebo. Of those on the drug, 63.2% lost at least 5%, against 27.1% on placebo.
Missed doses and restarting
Both labels say to skip a missed dose and take the next one as scheduled, without doubling up [1] [2]. If more than 3 days have passed, the labels restart at 0.6 mg.
The Saxenda label then repeats the weekly escalation. The reason given is the same: stomach side effects on restarting.
What these labels do not settle
These figures come from trials of the brand products, run alongside diet and activity counseling, so they describe the drug plus that support rather than the drug alone.
How the daily drug compares with a weekly one is covered in liraglutide vs semaglutide, and the weekly drug’s results in how much weight you can lose on semaglutide.
The labels list the abdomen, thigh and upper arm as sites, covered in peptide injection sites. To set options side by side, try the peptide comparator or the weight-loss peptide rankings.